EUVIMEDEUVIMED entdecken
Crossref

Rejuvenation of Tumor‐Specific T Cells via Ultrahigh DAR Antibody‐Polymeric Imidazoquinoline Complexes: Coordinated Targeting of PDL1 and Efficient TLR7/8 Activation in Intratumoral Dendritic Cells

Hongyu Chu, Yuezhan Shan, Zongyu Liu, Mengmeng Sun, Weidong Zhao, Xiao Xie, Kun Wang, Chenguang Yang, Xuedong Fang, Na Shen, Zhaohui Tang iD

Advanced Materials · 2025

DOI: 10.1002/adma.202412974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Hongyu Chu und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, Chi…. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Dendritic Cells, Toll-Like Receptor 8, B7-H1 Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Youth Innovation Promotion Association of the Chinese Academy of Sciences, Jilin Provincial Scientific and Technological Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intratumoral dendritic cells (DCs) are pivotal in tumor treatment due to their immature and pro‐tumoral state induced by the tumor microenvironment. Clinically, these immature DCs correlate with disease progression and recurrence, adversely affecting prognosis. Activation of DCs by the TLR7/8 agonist imidazoquinoline (IMDQ) has yielded promising results, but they are limited by systemic inflammation risks, and high programmed death ligand 1 (PDL1) expression on DCs impedes CD8 + T cell activity. Thus, the study introduces an antibody‐polymeric IMDQ complex (αPDL1‐PLG‐IMDQ) with an ultrahigh drug‐to‐antibody ratio, where αPDL1 is conjugated to Fc‐binding peptides on polymeric IMDQ. This complex targets high PDL1‐expressing intratumoral DCs with high probability, inducing PDL1‐mediated endocytosis to deliver IMDQ to TLR7/8 within endosomes, effectively activating DCs (CD11c + MHC II + : 2.33% versus 1.09%, CD11c + CD86 + : 2.49% versus 1.00% on tumors compared to phosphate‐buffered saline treatment) and priming T cells. It also blocks PDL1/PD1 interactions, enhancing tumor‐specific T‐cell activation and memory. Notably, αPDL1‐PLG‐IMDQ achieved a 97% tumor inhibition rate, prevented tumor regrowth in rechallenge experiments, and reduced lung metastases of tumors by 83%. These findings underscore its potential for intratumoral DC‐targeted immunotherapy and novel systemic IMDQ and checkpoint inhibitor combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 7Dendritic CellsToll-Like Receptor 8B7-H1 AntigenQuinolinesImidazolesPolymersT-LymphocytesAnimalsMiceHumansCell Line, TumorMice, Inbred C57BLFemaleCD8-Positive T-Lymphocytes

Stichwörter der Autor:innen

TLR7/8 agonistantibody‐drug conjugatedendritic cell targetingdrug deliveryimmune checkpoint blockade

Substanzen

Toll-Like Receptor 7Toll-Like Receptor 8B7-H1 AntigenQuinolinesImidazolesPolymers

Autor:innen und Institutionen

  • State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China.
  • Department of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
  • Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China.
  • The second hospital of Jilin University, Changchun, 130041, China.
  • The First Hospital of Jilin University, Changchun, 130021, China.

ORCID-Profile: Zhaohui Tang

Förderung

  • National Natural Science Foundation of China
  • Youth Innovation Promotion Association of the Chinese Academy of Sciences
  • Jilin Provincial Scientific and Technological Development Program
  • National Key R&D Program of China
  • National Key Research and Development Program of China

Zitieren

APA

Chu, H., Shan, Y., Liu, Z., Sun, M., Zhao, W., Xie, X., Wang, K., Yang, C., Fang, X., Shen, N., & Tang, Z. (2025). Rejuvenation of Tumor‐Specific T Cells via Ultrahigh DAR Antibody‐Polymeric Imidazoquinoline Complexes: Coordinated Targeting of PDL1 and Efficient TLR7/8 Activation in Intratumoral Dendritic Cells. Advanced Materials. https://doi.org/10.1002/adma.202412974

Vancouver

Chu H, Shan Y, Liu Z, Sun M, Zhao W, Xie X, et al. Rejuvenation of Tumor‐Specific T Cells via Ultrahigh DAR Antibody‐Polymeric Imidazoquinoline Complexes: Coordinated Targeting of PDL1 and Efficient TLR7/8 Activation in Intratumoral Dendritic Cells. Advanced Materials. 2025. doi:10.1002/adma.202412974

BibTeX
@article{Chu2025,
  author = {Chu, Hongyu and Shan, Yuezhan and Liu, Zongyu and Sun, Mengmeng and Zhao, Weidong and Xie, Xiao and Wang, Kun and Yang, Chenguang and Fang, Xuedong and Shen, Na and Tang, Zhaohui},
  title = {Rejuvenation of Tumor‐Specific T Cells via Ultrahigh DAR Antibody‐Polymeric Imidazoquinoline Complexes: Coordinated Targeting of PDL1 and Efficient TLR7/8 Activation in Intratumoral Dendritic Cells},
  journal = {Advanced Materials},
  year = {2025},
  doi = {10.1002/adma.202412974}
}
Kostenlos starten →